---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000101"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-13T23:56:27.525108+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals eliminates $4.75M in milestone payments to Sentrx; grants animal health license for royalty

## Summary
- Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.
- Kiora grants Sentrx exclusive license to KIO-201 patents for veterinary use; Kiora receives low single-digit royalty on net sales.
- Kiora retains optionality to source alternative manufacturing partners for KIO-201.
- KIO-201 is a modified hyaluronic acid for persistent corneal epithelial defects, a rare disease.

## SEC filing metadata
- accession: 0001372514-23-000101
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/0001372514-23-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000101/kprx-20230612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000101
- JSON: https://secwatch.observer/filing/0001372514-23-000101.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.